{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:10:06Z","timestamp":1779271806035,"version":"3.51.4"},"reference-count":30,"publisher":"American Society for Microbiology","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W911QY-20-9-0013"],"award-info":[{"award-number":["W911QY-20-9-0013"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"abstract":"<jats:p>Anti-SARS-CoV-2 immunoglobulin (human) investigational product (COVID-HIGIV) is a purified immunoglobulin preparation containing SARS-CoV-2 polyclonal antibodies. This single-center clinical trial aimed to characterize the safety and pharmacokinetics of COVID-HIGIV in healthy, adult volunteers.<\/jats:p>","DOI":"10.1128\/aac.01514-22","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T14:01:06Z","timestamp":1677592866000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study"],"prefix":"10.1128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-6838","authenticated-orcid":false,"given":"Sean T. H.","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Mirceta","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Lin","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarashon","family":"Broomes","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Jen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Abid","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Reich","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Hall","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-0284","authenticated-orcid":true,"given":"Judith A.","family":"Aberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y"},{"key":"e_1_3_3_5_2","unstructured":"FDA. 2021. Fact sheet for healthcare providers EUA of sotrovimab. https:\/\/www.fda.gov\/media\/149534\/download. Accessed 15 March 2022."},{"key":"e_1_3_3_6_2","unstructured":"FDA. 2021. Fact sheet for healthcare providers EUA of bamlanivimab and etesevimab. https:\/\/www.fda.gov\/media\/145802\/download. Accessed 15 March 2022."},{"key":"e_1_3_3_7_2","unstructured":"FDA. 2021. Fact sheet for healthcare providers EUA of REGEN-COV(casirivimab and imdevimab). https:\/\/www.fda.gov\/media\/145611\/download. Accessed 12 June 2022."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119657"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.02.008"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01064-3"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05235-3"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.18178"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00897-7"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00101-5"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104333"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222115"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700"},{"key":"e_1_3_3_21_2","unstructured":"VariZIG (Varicella zoster immunoglobulin [human]) sterile solution for injection. 2018. Saol Therapeutics Research Limited Roswell GA."},{"key":"e_1_3_3_22_2","unstructured":"HepaGam B (Hepatitis B immune globulin intravenous [human]). 2021. Saol Therapeutics Inc. Roswell GA."},{"key":"e_1_3_3_23_2","unstructured":"WinRho (Rho(D) immune globulin intravenous [human]). 2018. Saol Therapeutics Inc. Roswell GA."},{"key":"e_1_3_3_24_2","unstructured":"ANTHRASIL (Anthrax immune globulin intravenous [human]). 2015. Emergent BioSolutions Canada Inc. Winnipeg Manitoba Canada."},{"key":"e_1_3_3_25_2","unstructured":"CNJ-016 (Vaccinia immune globulin intravenous human VIGIV). 2018. Emergent BioSolutions Canada Inc. Winnipeg Manitoba Canada."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab854"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab540"},{"key":"e_1_3_3_28_2","unstructured":"BIVIGAM (Immune globulin intravenous [human] 10% liquid). 2019. Boca ADMA Biologics Inc. Boca Raton FL."},{"key":"e_1_3_3_29_2","unstructured":"GAMMAPLEX 10% (Immune globulin intravenous [human] 10% liquid). 2019. Bio Products Laboratory Limited Elstree Hertfordshire England."},{"key":"e_1_3_3_30_2","unstructured":"Privigen (Immune globulin intravenous [human] 10% liquid). 2019. CSL Behring LLC Bern Switzerland."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13050893"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01514-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01514-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T14:01:10Z","timestamp":1677592870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01514-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":30,"alternative-id":["10.1128\/aac.01514-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.01514-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"2022-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01514-22"}}